Venus Remedies shines on receiving Indonesian GMP for its Baddi unit

06 Feb 2014 Evaluate

Venus Remedies is currently trading at Rs. 230.25, up by 2.80 points or 1.23% from its previous closing of Rs. 227.45 on the BSE.

The scrip opened at Rs. 228.90 and has touched a high and low of Rs. 232.55 and Rs. 228.90 respectively. So far 2048 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 358.05 on 15-May-2013 and a 52 week low of Rs. 140.00 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs. 233.50 and Rs. 214.35 respectively. The current market cap of the company is Rs. 263 crore.

The promoters holding in the company stood at 43.99% while Institutions and Non-Institutions held 8.60% and 47.41% respectively.

Venus Remedies has got good manufacturing practices (GMP) certification from Indonesia for its unit located in Baddi, Himachal Pradesh. The Indonesian National Agency for Drug and Food Control (NADFC) granted the certification after an extensive review and audit of the facility. With this, the number of international GMP certifications for Venus Remedies has gone up to 22.

The NADFC is among the drug regulatory authorities of 44 countries which are part of the Pharmaceutical Inspection Convention/Co-operation Scheme (PIC/S). Venus Remedies has already got GMP certification from three other PIC/S members, including Ukraine, TGA-Australia, Indonesia and EU-GMP.

Indonesia represents one of the most attractive and flourishing markets for pharmaceutical companies looking to expand across the Asia-Pacific region. With a sizable population of 234 million, which is witnessing a rapidly expanding middle class, Indonesia is poised to emerge as a key market of growth for the health care & Pharmaceutical industry. Currently worth $4.5 billion, the Indonesia's pharmaceutical market is expanding at an annual rate of 12.5 percent. Pharmaceutical sales in Indonesia are expected to register a significant growth in 2012-16 at compound annual growth rate (CAGR) of 11.5% in terms of the local currency.

A potentially lucrative market for the company’s oncology product line, Indonesia records 170-120 new cancer cases annually in a population of every 1 lakh. Currently, the Indonesian Cancer market worth $88.58 Million (approximately) in 2013 and is expected to grow at 10%. Venus will commercially launch its products in Indonesia by the middle of this year and is projected to generate revenue of $1 million in the first year itself. With the launch of its oncology products in Indonesia, the company aims at capturing the maximum shares in the country‘s pharmaceutical market.

Venus Remedies Share Price

745.20 -7.70 (-1.02%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×